Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.deCODE genetics has launched deCODE PrCa, a reference laboratory test for common, single-letter variations in the human genome that the company has associated with increased risk of prostate cancer.
Subscribe to our email newsletter
deCODE believes the test will be useful for better predicting risk of prostate cancer, helping to optimize both screening and treatment. deCODE PrCa detects a total of six previously discovered SNPs that have been confirmed in many populations, as well as two SNPs on chromosomes X and 2 that were reported by deCODE scientists.
Kari Stefansson, CEO of decode, said: “Through deCODE PrCa, we are bringing together in one tool all of the major genetic risk factors for prostate cancer that we have discovered over the past eighteen months. We believe that this is a test with significant clinical utility for improving and personalizing the screening and treatment of one of the most common cancers.”